Rallybio Corporation shares fall 2.35% in premarket after selling REV102 project rights to Recursion Pharmaceuticals for $25 million.

Rallybio Corporation fell 2.35% in premarket trading after announcing the sale of its REV102 project rights to Recursion Pharmaceuticals for up to $25 million, including $7.5 million in upfront equity payments and $12.5 million in contingent equity payments and $5 million in milestone payments.